ARGX ArGEN-X SE

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

July 24, 2025



Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at . A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

Dial-in numbers:

Belgium                32 800 50 201

France                        33 800 943355

Netherlands                31 20 795 1090

United Kingdom        44 800 358 0970

United States                1 888 415 4250

Japan                        81 3 4578 9081

Switzerland                41 43 210 11 32

Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  and follow us on , , , and .

Contacts

Media:

Ben Petok

Investors:

Alexandra Roy



EN
24/07/2025

Underlying

ARGXArGEN-X SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ArGEN-X SE

 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx to Report Half Year 2025 Financial Results and Second Quarter B...

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025 July 24, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx...

July 24, 2025 1 EN
Jacob Mekhael ... (+6)
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
BFIT BASIC-FIT NV
PNL POSTNL NV ... (+8)

Morning Notes : ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONW...

: ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONWD BB, JDEP NA

BFIT BASIC-FIT NV
PNL POSTNL NV
QFG QUEST FOR GROWTH
ARGX ARGEN-X SE
UMI UMICORE
JDEP JDE PEET'S NV
BTLS BIOTALYS NV
ONWD ONWARD MEDICAL NV
07/01/25 July 1, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
ARGX ARGEN-X SE

argenx FDA FAERS reporting flags Vyvgart Hytrulo in routine update

Yesterday during trading hours, the FDA flagged worsening of CIDP with Vyvgart Hytrulo as a new safety signal via a routine update to the FDA adverse event reporting system (FAERS), which sent the argenx' stock down approx. 8%. While CIDP worsening was also reported in patients switching between treatments from IVig to SCig in the PATH study, physicians navigate treatment switches carefully, and based on argenx' own post-marketing surveillance,

07/01/25 July 1, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
ARGX ARGEN-X SE

argenx FIRST LOOK: ARGX-119 Ph1b shows POC in CMS, Ph3 in preparation

argenx announced its plan to advance the clinical development of ARGX-119 (muscle-specific kinase [MuSK] agonist antibody) to a registrational study in patients with congenital myasthenic syndromes (CMS) following the analysis of topline data from the phase 1b study, which showed consistent improvements through the 12-week study across multiple efficacy scores. This marks the 3rd candidate to advance to phase 3 from argenx' internal pipeline, which in our view supports the company's future growt...

06/30/25 June 30, 2025 1 EN
Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Thomas Couvreur
LEAS LEASINVEST REAL ESTATE SCA
RET RETAIL ESTATES NV
AGFB AGFA-GEVAERT NV
ARGX ARGEN-X SE
FUR FUGRO NV
06/30/25 June 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch